Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorolanib (Runbio Biotech)
- Development stage
- Phase 3
- Lead developer
- EyePoint Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravitreal
01
Overview
**EYP-1901** is an investigational, bioerodible sustained-release intravitreal insert containing the small-molecule tyrosine kinase inhibitor vorolanib. It uses EyePoint's Durasert E delivery matrix to provide local, near-zero-order release after a standard intravitreal injection. Vorolanib inhibits vascular endothelial growth factor receptor and platelet-derived growth factor receptor signaling, and preclinical work also supports inhibition of Janus kinase 1 mediated interleukin-6 inflammatory signaling. The product is in Phase 3 development for wet age-related macular degeneration and diabetic macular edema; it remains unapproved. ([eyepointpharma.com](https://eyepointpharma.com/wp-content/uploads/2024/09/Clinical-Reprint-Phase-I-DAVIO-Trial-by-Sunil-Patel-MD-091624.pdf))
- Other names
- DURAVYUvorolanib intravitreal insert
02
Targets
TYK2 (Tyrosine kinase 2)VEGFR2 (Vascular endothelial growth factor receptor 2)JAK2 (Janus kinase 2)FGFR (FGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)JAK3 (Janus kinase 3)PRKAA1 (AMP-activated protein kinase alpha catalytic subunit isoform alpha-1)PDGFRB (Platelet-derived growth factor receptor beta)JAK1 (Janus kinase 1)TEK (Tie2)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on vorolanib (Runbio Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorolanib (Runbio Biotech).